Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058944 | 0.77 | ALDH1A1 (0.48) | KMT2AALDH1A1LMNA | |
| SCHEMBL27770641 | 0.76 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL27770700 | 0.76 | KMT2A (0.51) | KMT2ASLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL10508162 | 0.76 | ALDH1A1 (0.44) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL27585717 | 0.75 | CHRNB4 (0.39) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL29108416 | 0.74 | KMT2A (0.48) | KMT2AALDH1A1LMNA | |
| SCHEMBL1873958 | 0.73 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL1878142 | 0.73 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL9944382 | 0.73 | KMT2A (0.58) | KMT2AALDH1A1LMNA | |
| SCHEMBL30731163 | 0.73 | KMT2A (0.58) | KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100260671-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260671-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | APP, HTT, SCN3A | KMT2A 4071/4885SLC6A3 38/4885SLC6A2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.